AGIOS PHARMACEUTICALS INC stock forecast: up to 24.71 USD AGIO stock price prognosis


Forecast for Fri 26 May 2023 price 25.29

AGIOS PHARMACEUTICALS INC stock price forecast for further price development up to 6.81% (time horizon: 1 day) and price target of 24.71 USD. Short-term (time horizon: 2 weeks) AGIOS PHARMACEUTICALS INC share price prediction for 2023-05-26 with daily closed price projections

Key Facts

Symbol AGIO 

ISIN US00847X1046 

CUSIP 00847X104

Currency USD

Category Pharmaceutical Preparations

Forecast price change %

Finance numbers

Revenue 203,196,000.0

Earnings per share -4.74

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

Vorasidenib is an orally available, selective brain-penetrant pan-IDH mutant inhibitor. Emerging areasNext generation targeted therapies. Tumor cells are generally observed to carry either an IDH1 or IDH2 mutation. The trial has completed enrollment. This trial has completed enrollment. PKR is the isoform of PK that is present in red blood cells, or RBCs. The initial four-year research term expired on May 17, 2020. Patent term adjustments or patent term extensions could result in later expiration dates. There are a number of marketed therapies available for treating patients with GDDs. These applications are submitted under Section 505(b)(1) of the FDCA. A ruling by the Supreme Court is expected sometime this year. In April 2014, the Clinical Trial (Regulation, (EU)) No 536/2014 was adopted. Strict deadlines have been established for the assessment of clinical trial applications. However, overall related timelines will be defined by the Clinical Trial Regulation. D.Decibel TherapeuticsMarc Tessier-Lavigne, Ph. As of December 31, 2020, 57% of our workforce were women. We expect to incur losses in the future and may never achieve or maintain profitability. We depend heavily on the success of our clinical product candidates. We are also pursuing product candidates to treat patients with GDDs. A broad range of legislative measures also have been introduced at the federal level. Each of these lawsuits was settled in 2012. Unpatented proprietary technical information and know-how can be difficult to protect. We cannot predict how federal agencies will respond to such Executive Orders. We do not maintain "key person" insurance for any of our executives or other employees.

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 34.72/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Fund ownership list is based on filling form information

Fund name Date Amount Profile
SPDR SERIES TRUST 2022-12-31 2044679 Long
SPDR SERIES TRUST 2022-12-31 5356 Long
FlexShares Trust 2023-01-31 5046 Long
RUSSELL INVESTMENT CO 2023-01-31 12218 Long


CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1578200 Schenkein David P 2023-03-13 SALE Accept Accept Accept Accept
1874199 Washburn Theodore James Jr. 2023-03-03 SALE Accept Reject Accept Reject

Bollinger Bollinger Bands for AGIOS PHARMACEUTICALS INC can provide the information where the market is moving based on price information.

AGIOS PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns AGIOS PHARMACEUTICALS INC.

On-Balance Volume information for AGIOS PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for AGIOS PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for AGIOS PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for AGIOS PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for AGIOS PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for AGIOS PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for AGIOS PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2023-05-12 24.71 2023-03-31 05:57
2023-04-27 24.10 2023-03-31 05:57
2023-04-28 24.14 2023-03-31 05:57
2023-05-01 24.18 2023-03-31 05:57
2023-05-02 24.24 2023-03-31 05:57
2023-05-03 24.30 2023-03-31 05:57
2023-05-05 24.43 2023-03-31 05:57
2023-05-15 24.78 2023-03-31 05:57
2023-05-16 24.84 2023-03-31 05:57
2023-05-04 24.35 2023-03-31 05:57
2023-05-08 24.49 2023-03-31 05:57
2023-05-09 24.56 2023-03-31 05:57
2023-05-10 24.61 2023-03-31 05:57
2023-05-11 24.66 2023-03-31 05:57
2023-05-19 25.01 2023-03-31 05:57
2023-05-25 25.23 2023-03-31 05:57
2023-05-17 24.90 2023-03-31 05:57
2023-05-18 24.95 2023-03-31 05:57
2023-05-22 25.06 2023-03-31 05:57
2023-05-23 25.12 2023-03-31 05:57
2023-05-24 25.18 2023-03-31 05:57
2023-05-26 25.29 2023-03-31 05:57
2023-04-07 23.22 2023-03-31 05:57
2023-04-12 23.29 2023-03-31 05:57
2023-04-03 22.63 2023-03-31 05:57
2023-04-04 22.67 2023-03-31 05:57
2023-04-05 22.89 2023-03-31 05:57
2023-04-06 23.20 2023-03-31 05:57
2023-04-10 23.20 2023-03-31 05:57
2023-04-11 23.28 2023-03-31 05:57
2023-04-13 23.34 2023-03-31 05:57
2023-04-14 23.40 2023-03-31 05:57
2023-04-17 23.58 2023-03-31 05:57
2023-04-18 23.63 2023-03-31 05:57
2023-04-19 23.80 2023-03-31 05:57
2023-04-20 23.77 2023-03-31 05:57
2023-04-21 23.80 2023-03-31 05:57
2023-04-24 23.82 2023-03-31 05:57
2023-04-25 23.95 2023-03-31 05:57
2023-04-26 24.01 2023-03-31 05:57

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.